I've already spoken about it briefly. It is important to focus on quality when it comes to tendering strategies. Of course, this should not be done entirely at the expense of cost, but I believe that the weighting of local origin and the quality of a product must be sufficiently important to reduce the consequences that the difference in costs could have. We have to make societal choices: if security of supply is important to us, these tenders are one way of showing it.
In terms of market share, I think there are several reasons why we lost it. In 2008, Québec and Canada were leaders in the biopharmaceutical field. Unfortunately, we lost many of these companies during the economic crisis. They are extremely expensive to start up and you have to be able to support them after their products are commercialized because, unfortunately, Canadian innovation...